NDA submission for Emcitate® successfully validated by the FDA Priority Review granted and PDUFA target action date set to September 28, 2026 Emcitate® (tiratricol) is eligible to receive a Priority Review Voucher (PRV) upon approval If approved, Emcitate® (tiratricol) would become the first approved treatment in the United States for MCT8 deficiency STOCKHOLM, SE / ACCESS Newswire / March 27, 2026 / Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "

Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets Study further details platform versatility through successful degradation of multiple therapeutically relevant targets, including inflammatory cytokine TNFα in macrophages and Schwann cells Copenhagen, Denmark, 30 March 2026 – Draupnir Bio (“Draupnir”), a biotechnology company harnessing the natural machinery

Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, an investigational small molecule prodrug of sialic acid (SA) being evaluated as a substr

Luxna Biotech Co., Ltd. and KH Neochem Co., Ltd.today announced the launch of a joint research initiative aimed at advancing next-generation drug discovery through the development of improved delivery technologies for nucleic acid therapeutics. Nucleic acid therapeutics are emerging as a promising modality for treating cancer and other challenging diseases. Unlike conventional small-molecule drugs and antibody therapeutics, they enable access to previously undruggable targets. However, instabil

The clinical trials assessed once-weekly Awiqli with mealtime insulin, oral anti-diabetic agents, and GLP-1 receptor agonists. Credit: Andrzej Rostek / Shutterstock.com. Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a basal insulin for adults with type 2 diabetes (T2D). It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA’s decision is based on data from the ONWARDS Phase

MONDAY, March 30, 2026 — Folks working a night shift have a harder time managing their type 2 diabetes , a new study says. Health care workers with diabetes – mainly nurses and midwives – have blood sugar levels that fluctuate more widely during a night shift, researchers reported recently in the journal Diabetic Medicine . This is likely due to the difficulty of maintaining a healthy diet when working the wee hours of the morning, researchers said. “What struck me is that these are people who

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and fu

iStock/ Grandbrothers The FDA has some big verdicts lined up in the second quarter, including one for a closely watched obesity drug that many anticipate will further intensify competition in weight loss. The second quarter is looking particularly front-loaded for the FDA, which in April is expected to make a handful of highly consequential decisions. One is for a rare disease with high unmet need, while another, for a melanoma treatment, could be a bellwether for how things might change at the

Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism

Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of lomitapide to include children 5 years of age and older with HoFH PARMA, Italy, March 30, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the